NCT07134205View on ClinicalTrials.gov

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

October 1, 2028

Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
DRUG

JMT101

JMT101, 6 mg/kg, administered by IV infusion once every two weeks (one treatment cycle is 4 weeks).

DRUG

Irinotecan

Irinotecan, 180mg/m\^2, administered by IV infusion once every two weeks (one treatment cycle is 4 weeks).

DRUG

Regorafenib

Regorafenib, 160 mg, taken orally once daily for the first 21 days of each 28-day cycle.

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY